Paul Tudor Jones’s Alexion Pharmaceuticals ALXN Stock Holding History

Paul Tudor Jones’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-422,200	Closed	-$64.6M	–	2136
2021 Q1	$64.6M	Buy	+422,200	New	+$65.3M	1.3%	8

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Paul Tudor Jones's ALXN Position: Q3 2021 in Review

Paul Tudor Jones sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 907,855 shares — an estimated $167M sold.

Paul Tudor Jones first reported a position in ALXN in Q2 2013 and held it in 28 quarters. The position peaked at $167M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Paul Tudor Jones reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Paul Tudor Jones sold 907,855 Alexion Pharmaceuticals shares in Q3 2021, an estimated $167M.
Paul Tudor Jones first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 28 quarters.
Paul Tudor Jones's Alexion Pharmaceuticals position peaked at $167M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.